学会発表（国内学会）

2023年度

2023.07 第30回日本遺伝子診療学会大会、第8回クリニカルバイオバンク学会シンポジウム合同学術集会

• がん遺伝子パネル検査の解析成功率の向上を目的とした後方視的解析
  井本 清美, 大池 信之, 小池 淳樹, 柳澤 信之, 野呂瀬 朋子, 大川 千絵, 島田 直樹, 新井 裕之, 武田 弘幸, 山本博幸, 若松 宏武, 佐藤 知雄, 砂川 優, 山野 嘉久.

2023.9 第59回日本胆道学会学術集会

• 切除不能または再発胆道癌患者に対する二次以降の薬物療法としてのFOLFOX療法の有効性及び安全性の検討（JON-2107B）
  千田彰彦、寺島健志、森實千種、戸髙 明子、梅本 久美子、川上裕次郎、上野誠、古瀬純司、永野浩和.

2023.10 第61回日本癌治療学会学術集会

• がん診療におけるリアルワールドデータ（RWD）収集に関する多施設共同研究
  松本繁巳, 武藤学, 福山啓太, 山本秀和, 室圭, 砂川優, 安井久晃, 大槻涼, 木村裕一, 岡田昌史, 西浦亮二, 湯川洋一郎.
• Cyber OncologyÒ を活用した進行胃癌治療のreal-world data 構築のための実行可能性研究
  松本繁巳, 門脇重憲, 町田望, 仁科智裕, 砂川 優, 前北隆雄, 西岡真理子, 後藤知之, 浜本康夫, 安井久晃, 川邉里紗, 岡田昌史, 武藤学, 室圭.
• 免疫チェックポイント阻害薬による間質性肺炎に対する治療実態調査
  野﨑智椰, 横溝綾子, 伊澤直樹, 森川慶, 武田弘幸, 新井裕之, 土井綾子, 堀江良樹, 久保田洋平, 幕内麻里, 森田一, 砂川優, 坂上逸孝.
• DEEPER 試験（mFOLFOXIRI+Cet vs Bev）のBRAF 追加解析報告
  間中大, 塩澤学, 河合毅, 太田博文, 安井久晃, 薮野太一, 鄭充善, 東風貢, 松橋延壽, 竹内正弘, 市川度, 藤井雅志, 砂川優, 辻晃仁.

2023.11 第78回日本大腸肛門病学会

• 切除不能進行再発大腸癌におけるがん遺伝子パネル検査の臨床実装
  砂川優.

2023.12 第36回日本バイオセラピィ学会学術集会総会

• 免疫チェックポイント阻害薬の効果は予測できるか？
  砂川優.

2024.1 第21回日本臨床腫瘍学会学術集会（JSMO2024）

• Clinical course of skin rashes caused by neoadjuvant gemcitabine plus S-1 for resectable pancreatic cancer.
  横溝綾子, 梅本久美子, 秋野幸, 森田一, 湊川紘子, 前田幹広, 久保田洋平, 武田弘幸, 土井綾子, 堀江良樹, 新井裕之, 伊澤直樹, 砂川優, 坂上逸孝.
• Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology®: Afeasibility study.
  町田望, 門脇重憲, 仁科智裕, 砂川優, 前北隆雄, 松本繁巳, 西岡真理子, 後藤知之, 浜本康夫, 安井久晃, 古田光寛, 梶原猛史, 新井裕之, 北野雅之, 長島文夫, 川邉里紗, 岡田昌史, 武藤学, 室圭.
• A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy.
  土井綾子, 加賀保行, 久保田洋平, 武田弘幸, 梅本久美子, 新井裕之, 堀江良樹, 小倉孝氏, 伊澤直樹, 堀部恵梨佳, 丹澤和雅, 砂川優.
• ゲノムガイドシステムを用いた包括的がんゲノムプロファイリングの実装データの構築.
  砂川優, 新井裕之, 山本博幸, 本吉愛, 右田王介, 大原樹, 古屋直樹, 井本清美, Stephan Het- tich, Ibrahim Avi Cemel, Lenka Kyjacova, Marc-Alexander Rauschendorf.
• Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13).
  夏目壮一郎, 関川高志, 髙金明典, 澤田憲太郎, 伴登宏行, 山田知弘, 中山裕史, 内間恭武, 白石 猛, 木﨑潤也, 古谷卓三, 竹内正弘, 市川度, 藤井雅志, 砂川優, 辻晃仁.
• Anti-EGFR therapy for RAS mutant mCRC without RAS mutations in ctDNA after 1st or 2nd-line chemotherapy: JACCRO CC-17.
  小野由香利, 伊澤直樹, 松原裕樹, 仁科慎一, 傳田忠道, 太田博文, 徳永卓哉, 陳凌風, 進藤吉明, 下川穂積, 藤田秀人, 岡本健, 石黒智之, 坂本康寛, 賀川義規, 佐竹悠良, 竹内正弘, 市川度, 藤井雅志, 砂川優.
• 患者と主治医の抗がん剤による副作用のつらさと休薬希望度の差に関する意識調査.
  小島拓, 伊澤直樹, 小倉孝氏, 土井綾子, 堀江良樹, 新井裕之, 武田弘幸, 久保田洋平, 梅本久美 子, 永田祐介, 内田吉保, 小川和起, 砂川優.
• がん患者および医療従事者を対象とした腫瘍内科領域における遠隔医療に関する意識調査－医療従事者からの回答結果報告－.
  谷口浩也, 松永拓真, 田村祐子, 川上武志, 佐竹悠良, 砂川優.
• 進行頸部食道扁平上皮癌患者に対してDocetaxel/Cisplatin/5-FU と強度変調放射線治療 IMRT を同時併用する根治的化学放射線療法の第Ⅱ相試験.
  渡辺晃識, 堅田親利, 川上正悟, 加藤健, 安藤孝将, 對馬隆浩, 野村基雄, 吉井貴子, 伊澤直樹, 小島隆嗣, 朴将源, 細川歩, 山本幸子, 石川秀樹, 浜本康夫.
• A prospective observational study of MSI screening in chemotherapy-naive advanced gastric cancer: WJOG13320GPS.
  加藤恭子, 小森梓, 廣中秀一, 杉本直俊, 西田謙太郎, 松山仁, 野長瀨祥兼, 坂口智紘, 近藤侑鈴, 中積宏之, 長瀬通隆, 伊澤直樹, 原田一顕, 岩槻政晃, 三梨桂子, 木藤陽介, 川上賢太郎, 陶山浩一, 吉村健一, 室圭.
• Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes.
  澁木太郎, 中村能章, 上野誠, 古川正幸, 川本泰之, 伊藤心二, 梅本久美子, 須藤研太郎, 佐藤太郎, 水野伸匡, 浅木彰則, 岡野尚弘, 清水怜, 大坪公士郎, 松本俊彦, 藤澤孝夫, 坂東英明, 吉野孝之, 森実千種, 池田公史.
• The utility of circulating tumor DNA in gastrointestinal stromal tumor -a pooled analysis of SCRUM-Japan trials-.
  橋本直佳, 中村能章, 小松嘉人, 高橋直樹, 岡野尚弘, 森実千種, 大坪公士郎, 太田高志, 沖英次, 仁科智裕, 安井久晃, 川上尚人, 江崎泰斗, 町田望, 土井綾子, 朴将源, 工藤敏啓, 藤澤孝夫, 坂東英明, 吉野孝之.
• A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study).
  若林宗弘, 谷口浩也, 結城敏志, 武田弘幸, 三谷誠一郎, 奥村祐太, 赤澤直也, 山口和久, 牧山明資, 工藤敏啓, 工藤千穂, 盛啓太, 室圭.

2024.3 第96回日本胃癌学会総会

• 再発した胃癌・胃食道接合部癌におけるリキッドバイオプシーのCGP検査：Liquid-GEAR試験 A liquid biopsy-based CGP testing in recurrent gastric or GEJ cancer: Liquid-GEAR study
  武田 弘幸, 石黒 敦, 川端 良平, 仁科 慎一, 高橋 正純, 鈴木 修平, 鈴木 崇久, 松山 仁, 髙橋 政樹, 砂川 優.

2022年度

2022.04 DCT産学連携勉強会

• 遠隔医療を用いた治験プレスクリーニング検査の実装
  砂川優

2022.06 第7回がんサポーティブケア学会学術集会

• がんの日常診療におけるePROによる症状モニタリングの有用性の評価および、有害事象とQoLの実態に関するレジストリ研究（RegiPRO study）
  堀江良樹, 宮路天平, 土井綾子, 川口崇, 小倉孝氏, 兼安貴子, 長島文夫, 中島貴子, 山口拓洋
• 切除可能大腸がん高齢患者の高齢者機能評価と臨床経過
  宇井一眞、土井綾子、武田弘幸、梅本久美子、新井裕之、堀江良樹、水上拓郎、伊澤直樹、小倉孝氏、砂川優

2022.09 CRCと臨床試験のあり方を考える会議

• 臨床試験における遠隔同意について考える
  内山修太朗, 原直也, 川名部新, 中川朋子, 中村祐太, 月山秀一, 水上拓郎, 曽根正勝

2022.09 第23回日本内分泌学会関東甲信越支部学術集会

• 食道癌に対してニボルマブ治療開始13か月後、尿糖自己測定によりirAEによる劇症1型糖尿病を早期に捉えた1例
  内山修太朗, 原直也, 川名部新, 中川朋子, 中村祐太, 月山秀一, 水上拓郎, 曽根正勝

2022.09 第76回日本食道学会学術集会

• 食道扁平上皮癌・胃食道接合部癌におけるctDNAを用いた治療戦略
  Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Kumiko Umemoto, Naoki Izawa, Takashi Ogura, Yu Sunakawa.

2022.10 第60回日本癌治療学会学術集会

• RAS野生型大腸癌における血管新生因子と2次治療FOLFIRI+RAMの効果:JACCRO CC-16AR
  砂川優, 安井久晃, 塩澤学, 武田弘幸, 赤澤直也, 佐川保, 白石和寛, 大北仁裕, 奥山浩之, 結城敏志, 谷中昭子, 阿部由紀子, 市川度, 藤井雅志, 辻晃仁.
• TRUSTY試験における血管新生関連遺伝子とFTD/TPI+BEVの有効性の検討
  渡邉 純, 久保木 恭利, 寺澤 哲志, 川上 尚人, 横田 満, 中村 将人, 小髙 雅人, 沖 英次, 砂川 優, 石原 聡一郎, 谷口 浩也, 中島 貴子, 森田 智視, 白尾 國昭, 吉野 孝之.
• RAS 野生型切除不能大腸癌における二次治療FOLFIRI＋ラムシルマブ療法の前治療レジメン別の効果：JACCRO CC-16サブ解析
  片岡 幸三, 辻 晃仁, 勝屋 弘雄, 藤田 正太郎, 弓削 浩太郎, 木藤 陽介, 福永 睦, 中村 将人, 佐川 保, 渡邉 貴紀, 塩澤 学, 砂川 優, 竹内 正弘, 市川 度, 藤井 雅志.
• RAS/BRAF野生型進行再発大腸癌患者における血中バイオマーカーのダイナミクスと抗EGFR抗体リチャレンジの有効性。REMARRY試験/PURSUIT試験
  太田 高志, 山崎 健太郎, 賀川 義規, 小谷 大輔, 坂東 英明, 加藤 健志, 沖 英次, 篠崎 英司, 砂川 優, 結城 敏志, 中島 裕理, 中村 能章, 若林 将史, 谷口 浩也, 吉野 孝之.
• リアルワールドデータ（RWD）から見た小腸癌のゲノムランドスケープ
  武田 弘幸, 山本 博之, 及川 律子, 梅本 久美子, 土井 綾子, 新井 裕之, 堀江 良樹, 久保田 洋平, 小倉 孝氏, 伊澤 直樹, Jay A Moore, Ethan Sokol, 砂川 優.
• 当院における抗EGFR抗体薬投与患者に対する診察前面談の取り組み
  横溝 綾子, 森田 一, 幕内 麻里, 湊川 紘子, 計良 貴之, 熱方 智和子, 堀江 良樹, 伊澤 直樹, 坂上 逸孝, 田中 恒明, 砂川 優.
• 進行胃癌・大腸癌における治療前の血中循環腫瘍DNA検出の臨床的妥当性
  青木 優, 中村 能章, 谷口 浩也, 小松 嘉人, 砂川 優, 塩澤 学, 太田 高志, 江崎 泰斗, 山﨑 健太郎, 佐竹 悠良, 松橋 延壽, 後藤 昌弘, 賀川 義規, 仁科 智裕, 吉野 孝之.

2023.02 第55回制癌剤適応研修会

• 初診時切除不能と判断したがConversion surgery後も長期生存している非乳頭部十二指腸癌の1例
  増田哲之, 小林慎二郎, 水上拓郎, 野呂瀬朋子, 梅澤早織, 井田圭亮, 土橋篤仁, 小泉哲, 砂川優, 大池信之, 大坪毅人
• 切除可能膵頭部癌に対するNAC-GSについての現況と課題
  小林慎二郎, 増田哲之, 梅本久美子, 梅澤早織, 井田圭亮, 土居綾子, 土橋篤仁, 小泉哲, 砂川優, 大坪毅人

2023.02 第95回日本胃癌学会学術集会

• 胃癌患者における免疫関連有害事象の予測因子としての自己免疫疾患関連抗体の臨床的意義
  Naoki Izawa, Hiroyuki Takeda, Yohei Kubota, Ayako Doi, Yoshiki Horie, Hiroyuki Arai, Kumiko Umemoto, Yu Sunakawa.
• Treatment for elderly gastric cancer patients -Geriatric assessment and clinical outcomes-
  Ayako Doi, Yohei Kubota, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Yoshiki Horie, Naoki Izawa, Takashi Ogura, Yu Sunakawa.
• 胃がん患者における腸内細菌叢と臨床的特徴の検討：SCRUM-Japan MONSTAR-SCREEN
  澤田 憲太郎, 山下 理宇, 酒井 俊輔, 吉河 歩, 洞澤 智至, 中村 能章, 藤澤 孝夫, 門脇 重憲, 安井 久晃, 高橋 直樹, 町田 望, 牧山 明資, 後藤 昌弘, 砂川 優, 江﨑 泰斗, 山﨑 健太郎, 辻 晃仁, 吉野 孝之.
• 進行胃癌における腸内細菌関連バイオマーカー
  砂川 優.
• 高齢胃癌患者における高齢者機能評価と臨床経過
  土井 綾子, 久保田 洋平, 武田 弘幸, 梅本 久美子, 新井 裕之, 堀江 良樹, 伊澤 直樹, 小倉 孝氏, 砂川 優.
• 胃癌ゲノムプロファイリングによる druggable alteration の同定
  新井 裕之, 山本 博幸, 武田 弘幸, 久保田 洋平, 土井 綾子, 堀江 良樹, 梅本 久美子, 伊澤 直樹, 砂川 優.
• 胃癌患者における免疫関連有害事象の予測因子としての自己免疫疾患関連抗体の臨床的意義
  伊澤 直樹, 武田 弘幸, 久保田 洋平, 土井 綾子, 堀江 良樹, 新井 裕之, 梅本 久美子, 砂川 優.

2023.03 第20回日本臨床腫瘍学会学術集会

• RAS変異型切除不能進行・再発大腸癌患者における化学療法後のctDNA中RAS遺伝子変異ステータス：RASMEX study (JACCRO CC-17)
  伊澤　直樹, 松原 裕樹, 仁科 慎一, 塩澤 学, 傳田 忠道, 太田 博文, 根来 裕二, 田中 千弘, 川上 尚人, 松岡 宏, 田邊 裕貴, 池永 雅一, 奥田 博介, 石黒 敦, 賀川 義規, 佐竹 悠良, 砂川 優, 竹内 正弘, 市川 度, 藤井 雅志
• 切除不能なvulnerable大腸がん患者に関する実態調査：治療パターンと2次治療移行に関連する因子の検討
  伊澤　直樹, 木藤 陽介, 三谷 誠一郎, 日野 佳織, 川上 賢太郎, 花村 文康, 山本 祥之, 庄司 広和, 小森 梓, 朴 将源, 土橋 賢司, 馬場 英司, 加藤 恭子, 野長瀨 祥兼, 松本 俊彦, 古田 光寛, 川上 尚人
• A study to evaluate the clinical utility of stress data collection in cancer patients treated with chemotherapy
  Ayako Doi, Erika Horibe, Yohei Kubota, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Yoshiki Horie, Naoki Izawa, Takashi Ogura, Kazumasa Tanzawa, Yasuyuki Kaga, Tomomi Shibuya , Satoshi Muta, and Yu Sunakawa.
• Efficacy and safety of fruquintinib in Japanese patients with refractory metastatic colorectal cancer from FRESCO-2
  Daisuke Kotani, Takayuki Yoshino, Toshiki Masuishi, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Hisato Kawakami, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Cathy Eng, Stacey Ukrainskyj, Rajash Pallai, Shivani Nanda, Zhao Yang, William Schelman, Marek Kania, Taroh Satoh.
• RAS野生型切除不能進行再発大腸癌に対する血中RAS変異と2次治療FOLFIRI+ramucirumab療法の効果: JACCRO CC-16AR
  安井 久晃, 松浦 正徒, 峯 孝志, 湯浅 康弘, 渡邉 貴紀, 金城 達也, 大北 仁裕, 奥山 浩之, 結城 敏志, 宮川 公毅, 小原 采奈, 市川 度, 藤井 雅志, 辻 晃仁.
• RAS野生型切除不能進行再発大腸癌に対するm-FOLFOXIRI+cetuximab vs. bevacizumabの生存解析: DEEPER試験(JACCRO CC-13)
  辻 晃仁, 遠藤 出, 小林 建司, 楠本 哲也, 湯浅 康弘, 三輪 啓介, 東風 貢, 佐川 保, 小髙 雅人, 久保田 祐太郎, 砂川 優, 関川 高志, 中村 将人, 市川 度, 藤井 雅志.
• がん薬物療法患者におけるストレスデータ収集の有用性に関する研究
  土井 綾子,,堀部 恵梨佳, 久保田 洋平, 武田 弘幸, 梅本 久美子, 新井 裕之, 堀江 良樹, 小倉 孝氏, 伊澤 直樹, 丹澤 和雅, 加賀 保行, 澁谷 朋実, 牟田 敏志, 砂川 優.
• 切除不能進行大腸癌におけるCDC37遺伝子発現のレゴラフェニブ療法の効果予測
  新井 裕之, 傳田 忠道, 久保田 洋平, 武田 弘幸, 土井 綾子, 堀江 良樹, 梅本 久美子, 伊澤 直樹, 砂川 優.
• RAS変異型切除不能進行・再発大腸癌患者における化学療法後のctDNA中RAS遺伝子変異ステータス：RASMEX study (JACCRO CC-17)
  伊澤 直樹, 松原 裕樹, 仁科 慎一, 塩澤 学, 傳田 忠道, 太田 博文, 根来 裕二, 田中 千弘, 川上 尚人, 松岡 宏, 田邊 裕貴, 池永 雅一, 奥田 博介, 石黒 敦, 賀川 義規, 佐竹 悠良, 砂川 優, 竹内 正弘, 市川 度, 藤井 雅志.
• 抗EGFR抗体薬併用化学療法進行再発大腸癌患者に対する2次治療FOLFIRI/ラムシルマブ併用療法の第II相試験：JACCRO CC-16 Update解析
  間中 大, 辻 晃仁, 澁谷 雅常, 石橋 敬一郎, 薮野 太一, 岡村 修, 古谷 卓三, 田中 千弘, 中村 将人, 佐川 保, 渡邉 貴紀, 塩澤 学, 砂川 優, 太田 博文, 小髙 雅人, 奥山 浩之, 大北 仁裕, 竹内 正弘, 市川 度, 藤井 雅志.
• 切除不能なvulnerable大腸がん患者に関する実態調査：治療パターンと2次治療以降に関連する因子の検討
  伊澤 直樹, 木藤陽介, 他.
• 切除不能なvulnerable大腸がん患者に関する実態調査：1次治療症例210例の検討
  日野佳織, 伊澤直樹, 木藤陽介, 他.
• 切除不能なvulnerable大腸がん患者に関する実態調査：2次治療症例の検討
  川上賢太郎, 伊澤直樹, 木藤陽介, 他.
• BRAF V600E変異型切除不能進行・再発大腸癌に対するFOLFOXIRI+/-Bevacizumab療法とDoublet療法の有効性及び安全性に関する後方視的検討
  中村真穂, 伊澤直樹, 下崎啓太郎, 他.
• 高齢者切除不能・再発胃癌に対するS-1単剤療法とS-1/L-OHP併用療法のランダム化第２相試験
  庄司広和, 伊澤直樹, 牧山明資, 他.

学会発表（国際学会）

2024年度

2024.06 ASCO

• Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).
  Hiroaki Kanemura, JUNKO TANIZAKI, Koji Matsumoto, Toshiki Masuishi, Taichi Isobe, Hiroaki Kodama, Toshio Shimizu, Yu Sunakawa, Yasutaka Chiba, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hidetoshi Hayashi.
• Efficacy and safety of combination therapy with binimetinib, encorafenib, and cetuximab for BRAF non-V600E mutated metastatic colorectal cancer: Results from a phase 2 BIG BANG trial (EPOC1703).
  Daisuke Kotani, Hideaki Bando, Hiroya Taniguchi, Toshiki Masuishi, Taito Esaki, Yu Sunakawa, Yoshito Komatsu, Eiji Shinozaki, Taroh Satoh, Tomohiro Nishina, Yoshiaki Nakamura, Yuichi Mikamoto, Masashi Wakabayashi, Akihiro Sato, Shogo Nomura, Hiromichi Ebi, Takayuki Yoshino.
• A multicenter single-arm phase II study examining the efficacy of TNT for locally advanced rectal cancer: ENSEMBLE-2.
  Koji Ando, Yoshinori Kagawa, Mamoru Uemura, Jun Watanabe, Masaaki Miyo, Yasunori Emi, Nobuhisa Matsuhashi, Naoki Izawa, Osamu Muto, Tatsuya Kinjo, Yujiro Nishizawa, Tsuyoshi Hata, Yusuke Suwa, Takuya Honboh, Jesse Yu Tajima, Yu Sunakawa, Koji Oba, Ichiro Takemasa, Eiji Oki.

2023年度

2023.06 ASCO

• Survival analysis by tumor response of nivolumab treatment in previously treated advanced gastric cancer from the DELIVER trial (JACCRO GC-08).
  Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii.
• Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.
  Takeshi Kuwata, Yoshiaki Nakamura, Tomohiro Nishina, Naoki Takahashi, Hiroto Narimatsu, Hourin Cho, Chiaki Inagaki, Shigenori Kadowaki, Yoshinaga Okugawa, Sawako Matsuzaki, Naohiro Tomita, Hisateru Yasui, Yu Sunakawa, Manami Matsukawa, Kaori Kimura, Yumie Hiraoka, Makoto Hirata, Issei Imoto, Shinji Kosugi, Takayuki Yoshino.
• Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
  Hiroya Taniguchi, Masataka Yagisawa, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Iver Odegaard, Satoshi Fujii, Shogo Nomura, Akihiro Sato, Takayuki Yoshino, Yoshiaki Nakamura.
• NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
  Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino.
• Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
  Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Erika P. Hamilton, Hidetoshi Hayashi, Seung Tae Kim, Keun-Wook Lee, Bradley J. Monk, Danny Nguyen, Alicia Frances Clare Okines, David M. O’Malley, Paula R Pohlmann, Martin Reck, Evan Y. Yu, Roman Groisberg, Jorge Ramos, Qianwen Tan, Tom Stinchcombe, Tanios S. Bekaii-Saab.

2023.07 ESMO-GI

• RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC: the RASMEX study (JACCRO CC-17) .
  Shinichi Nishina, Naoki Izawa, Megumu Watabe, Toshihiko Matsumoto, Masato Kataoka, Akinori Sugaya, Tomomi Kashiwada, Eiji Oki, Akitaka Makiyama, Yoshihisa Yaguchi, Takashi Ohta, Tatsuya Toyokawa, Yasuyuki Miura, Kazuma Kobayashi, Yosuke Kito, Osamu Muto, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.
• Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO.
  Yu Sunakawa, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Takahisa Kyogoku, Tamotsu Sagawa, Yutaro Kubota, Toshiki Masuishi, Masahito Kotaka, Takashi Sekikawa, Ken Shimada, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, and Akihito Tsuji.

2023.10 ESMO

• The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer patients with RAS mutation negative in circulating-tumor DNA after 1st or 2nd-line chemotherapy.
  Naoki Izawa, Toshihiro Kudo, Satoshi Yuki, Michio Nakamura, Dai Manaka, Yosuke Kumekawa, Takashi Mine, Tatsuya Okuno, Hisanobu Oda, Tamotsu Sagawa, Takashi Kawai, Tatsushi Shingai, Masahito Kotaka, Kenji Kobayashi, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.
• 555MO – Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13).
  Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, M. Matsuura, Y. Shinohara, T. Miyake, T. Sagawa, C. Tanaka, S. Okamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji.
• 1549P – A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial.
  H. Takeda, R. Kawabata, A. Ishiguro, S. Nishina, M. Takahashi, S. Suzuki, T. Suzuki, J. Matsuyama, A. Okita, H. Miyagaki, N. Takegawa, T. Nomura, Y. Kito, H. Yabusaki, Y. Negoro, A. Makiyama, M. Nakamura, M. Takahashi, Y. Sunakawa.
• 1547P – SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer.
  C. Inagaki, R. Matoba, H. Iijuma, J. Hihara, H. Yasui, M. Tsuda, T. Suzuki, A. Makiyama, H. Yabusaki, J. Matsuyama, M. Takahashi, Y. Kito, Y. Akamaru, A. Ishiguro, R. Kawabata, Y. Sakamoto, E. Inoue, W. Ichikawa, M. Fujii, Y. Sunakawa.

2023.12 ESMO Asia

• Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC).
  Koichi Goto, Alison M. Schram, Dong-Wan Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, Michael Duruisseaux, Kumiko Umemoto, Joon Oh Park, Natasha Leighl, Teresa Macarulla, Stephen V. Liu, Mohammed Najeeb Al Hallak, James Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, Shola Adeyemi, Shekeab Jauhari, Alexander E. Drilon.

2024.1 ASCO-GI

• Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX therapy in Japan: A retrospective observational study using administrative database.
  Yu Sunakawa, Chaochen Wang, Yongzhe Piao, Long Jin, Yoshinori Tanizawa, Zhihong Cai, Yoshinori Kagawa.
• A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
  Hiroyuki Arai, Eisuke Inoue, Masanori Terashima, Eishi Baba, Nobuhisa Matsuhashi, Kei Muro, Toshifumi Yamaguchi, Satoshi Yuki, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.
• Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy.
  Yu Aoki, Yoshiaki Nakamura, Yoshito Komatsu, Hiroya Taniguchi, Yu Sunakawa, Manabu Shiozawa, Chiyoe Kitagawa, Takashi Ohta, Nobuhisa Matsuhashi, Kentaro Yamazaki, Shogen Boku, Naoki Takahashi, Taito Esaki, Hisato Kawakami, Yoshinori Kagawa, Tomohiro Nishina, Kensei Yamaguchi, Hideaki Bando, Takayuki Yoshino.
• Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR).
  Kota Ouchi, Akihito Tsuji, Manabu Shiozawa, Takashi Kawai, Hisateru Yasui, Hirofumi Ota, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Toru Miyake, Tatsuro Yamaguchi, Masato Matsuura, Tamotsu Sagawa, Akitaka Makiyama, Kunihiko Wakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Chikashi Ishioka, Yu Sunakawa.
• Efficacy of biomarker-matched therapy in clinical trials for advanced gastrointestinal cancers: A pooled analysis of SCRUM-Japan studies.
  Tadayoshi Hashimoto, Takao Fujisawa, Nozomu Machida, Akitaka Makiyama, Shogen Boku, Shigenori Kadowaki, Naoki Takahashi, Eiji Oki, Chigusa Morizane, Yu Sunakawa, Yoshito Komatsu, Naohiro Okano, Taito Esaki, Takashi Ohta, Takeshi Kato, Hiroshi Ozaki, Naoko Iida, Yoshiaki Nakamura, Hideaki Bando, Takayuki Yoshinoa.
• Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.
  Haeseong Park, Tanios S. Bekaii-Saab, Sunnie S. Kim, Michael J. Pishvaian, Yu Sunakawa, Suneel Deepak Kamath, Akihito Kawazoe, Kei Muro, David Bing Zhen, Hidekazu Hirano, Erika Maestas, Patrick Grierson, Naotoshi Sugimoto, Kensei Yamaguchi, Michelle Ubowski, Qianwen Tan, David E. Adelberg, John H Strickler.
• An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study.
  Shun Yamamoto, Ken Kato, Hiroshi Saeki, Shigenori Kadowaki, Keiko Minashi, Yuki Kasahara, Motoo Nomura, Tomoyo Yasuda, Yusuke Sato, Kazuo Koyanagi, Naoki Izawa, Morihito Okada, Hironaga Satake, Shuko Morita, Masahiro Goto, Takako Yoshii, Sachiko Yamamoto, Makiko Izawa, Kohei Uemura, Kei Muro.
• Safety and efficacy of chemotherapy for patients (pts) with unresectable pancreatic cancer (uPC) concomitant with collagen disease: A multicenter retrospective observational study .
  Hiroyuki Asama, Hiroyuki Okuyama, Yasuyuki Kawamoto, Kumiko Umemoto, Takuo Yamai, Satoshi Kobayashi, Masafumi Watanabe, Yasuo Hamamoto, Takaaki Furukawa, Yohei Kitano, Masayo Motoya, Yuko Suzuki, Akihiro Ohba, Kazuo Watanabe, Naohiro Okano, Kazuhiko Shioji, Noritoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Makoto Ueno.
• Comprehensive clinico-molecular profile and efficacy of anti-HER2 therapy for HER2-amplified biliary tract cancer.
  Kanae Inoue, Yoshiaki Nakamura, Bennett Caughey, Binbin Zheng-Lin, Makoto Ueno, Masayuki Furukawa, Yasuyuki Kawamoto, Shinji Itoh, Kumiko Umemoto, Kentaro Sudo, Taroh Satoh, Nobumasa Mizuno, Takeshi Kajiwara, Takao Fujisawa, Hideaki Bando, Takayuki Yoshino, John H. Strickler, Tanios Bekaii-Saab, Chigusa Morizane, Masafumi Ikeda.
• Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
  Taro Shibuki, Yoshiaki Nakamura, Makoto Ueno, Masayuki Furukawa, Yasuyuki Kawamoto, Shinji Itoh, Kumiko Umemoto, Kentaro Sudo, Taroh Satoh, Nobumasa Mizuno, Akinori Asagi, Naohiro Okano, Satoshi Shimizu, Tanios Bekaii-Saab, John H. Strickler, Takao Fujisawa, Hideaki Bando, Takayuki Yoshino, Chigusa Morizane, Masafumi Ikeda.

2022年度

2022.06 ASCO Annual Meeting

• Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
  Hiroyuki Arai, Yan Yang, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Zhang Wu, Alan P. Venook, Yu Sunakawa, Heinz-Josef Lenz.
• Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
  Yoshinori Kagawa, Daisuke Kotani, Hideaki Bando, Naoki Takahashi, Tetsuya Hamaguchi, Akiyoshi Kanazawa, Takeshi Kato, Koji Ando, Hironaga Satake, Eiji Shinozaki, Yu Sunakawa, Atsuo Takashima, Kentaro Yamazaki, Satoshi Yuki, Hiromichi Nakajima, Yoshiaki Nakamura, Masashi Wakabayashi, Hiroya Taniguchi, Takashi Ohta, Takayuki Yoshino.
• Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
  Satoshi Yuki, Yu Sunakawa, Kentaro Yamazaki, Hiromichi Shirasu, Hiroya Taniguchi, Toshiki Masuishi, Manabu Shiozawa, Hideaki Bando, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake, Atsuo Takashima, Yukiko Abe, Shogo Nomura, Takayuki Yoshino.
• Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.
  Bennett Adam Caughey, Kumiko Umemoto, Michelle Green, Masafumi Ikeda, Rachel D’Anna, Makoto Ueno, Donna Niedzwiecki, Hiroya Taniguchi, Daniel Walden, Yoshito Komatsu, Katherine I. Zhou, Taito Esaki, Ryne Ramaker, Tadamichi Denda, Michael Datto, Hideaki Bando, Tanios S. Bekaii-Saab, Takayuki Yoshino, John H Strickler, Yoshiaki Nakamura.
• Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) cancer.
  Alison M Schram, Koichi Goto, Dong-Wan Kim, Patricia Martin-Romano, Sai-Hong I Ou, Grainne M O’Kane, Eileen M O’Reilly, Kumiko Umemoto, Michaël Duruisseaux, Cindy Neuzillet, Frans Opdam, Jordi Rodon Ahnert, Misako Nagasaka, Benjamin A Weinberg, Teresa Macarulla, Andrew K Joe, Jim Ford, Viktoriya Stalbovskaya, Ernesto Wasserman, Alexander E Drilon.

2022.06 ASCO Plenary Series

• First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety.
  John H Strickler, Hironaga Satake, Antoine Hollebecque, Yu Sunakawa, Pascale Tomasini, David Lawrence Bajor, Martin H. Schuler, Rona Yaeger, Thomas J. George, Ignacio Garrido-Laguna, Andrew L. Coveler, Mark David Vincent, Gerald Steven Falchook, Timothy F. Burns, Sun Young Rha, Charlotte Rose Lemech, Dejan Juric, Pegah Jafarinasabian, Qui Tran, David Hong.

2022.06 ESMO-GI

• An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18).
  Y. Sunakawa, C. Inagaki, S. Yuki, M. Shiozawa, A. Tsuji, R. Matoba, E. Inoue, K. Muro, W. Ichikawa.
• Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
  Y. Kagawa, D. Kotani, H. Bando, N. Takahashi, Y. Horita, A. Kanazawa, T. Kato, K. Ando, H. Satake, E. Shinozaki, Y. Sunakawa, A. Takashima, K. Yamazaki, S. Yuki, H. Nakajima, Y. Nakamura, M.Wakabayashi, H. Taniguchi, T. Ohta, T. Yoshino.
• Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16.
  Y. Okita, A. Tsuji, T. Watanabe, H. Satake, M. Goto, H. Yasui, M. Nakamura, T. Sagawa, K. Kataoka, M. Shiozawa, Y. Sunakawa, H. Ota, M. Kotaka, K. Miwa, Y. Kobayashi, H. Okuyama, M. Kochi, T. Masuishi, M. Takeuchi, W. Ichikawa, M. Fujii.
• An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study.
  H. Kawakami, S. Oyamada, Y. Horie, S. Fumita, N. Izawa, T. Miyaji, T. Kawaguchi, T. Yamaguchi, T. Nakajima.

2022.09 ESMO

• Final analysis of clinical outcomes in the DELIVER trial: Observational study of nivolumab treatment in advanced gastric cancer (JACCRO GC-08).
  Y Sunakawa, E Inoue, Y Sakamoto, R Kawabata, A Ishiguro, Y Akamaru, Y Kito, M Takahashi, J Matsuyama, H Yabusaki, A Makiyama, T Suzuki, M Tsuda, H Yasui, H Kawakami, TE Nakajima, K Muro, R Matoba, W Ichikawa, M Fujii.

2023.01 ASCO-GI

• Outcomes of FOLFIRINOX and gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1: A propensity score–matching analysis.
  Naohiro Okano, Kentaro Sakamaki, Takafumi Mie, Kazuo Watanabe, Satoshi Kobayashi, Akiko Todaka, Yuko Suzuki, Hidetoshi Kitamura, Kazunari Tanaka, Kei Nakagawa, Keiko Kamei, Kumiko Umemoto, Nobuaki Azemoto, Yasuyuki Kawamoto, Hiroaki Yanagimoto, Kunihiro Tsuji, Hiroshi Imaoka, Takeshi Terashima, Makoto Ueno, Junji Furuse.
• Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN.
  Shun Tezuka, Shunsuke Sakai, Riu Yamashita, Satoshi Horasawa, Takao Fujisawa, Kentaro Sawada, Ayumu Yoshikawa, Yoshiaki Nakamura, Kumiko Umemoto, Nobuhiro Shibata, Koushiro Ohtsubo, Shinji Itoh, Akiko Todaka, Kentaro Sudo, Masayuki Furukawa, Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, Takayuki Yoshino.
• Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as second-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR.
  Yu Sunakawa, Hisateru Yasui, Manabu Shiozawa, Hiroyuki Takeda, Naoya Akazawa, Tamotsu Sagawa, Kazuhiro Shiraishi, Yoshihiro Okita, Hiroyuki Okuyama, Satoshi Yuki, Shoko Yanaka, Koutatsu Matsushima, Koki Miyakawa, Ayana Kobara, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji.
• Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO.
  Yu Sunakawa, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Akihito Tsuji.
• Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
  Hiroo Ishida, Yu Sunakawa, Yasuhiro Kodera, Kazuhiro Yoshida, Mitsugu Kochi, Yoshihiro Kakeji, Takeshi Sano, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.

論文業績（和文）

2023年度

《原著・総説・解説》

1. 若年膵癌とKRAS変異

• 胆と膵, 44(7)：661-663.
• 梅本久美子

2. FOLFOX+CET/PANI 療法,　FOLFIRI＋CET/PANI療法

• ガイドラインに沿った大腸癌薬物療法の要点と盲点,第2版、Ⅱ２：29-35.
• 武田弘幸、砂川優

3. 消化管がん（食道、胃、大腸）診療におけるゲノム医療の位置づけ

• 腫瘍内科, 31(6):688-694.
• 新井　裕之、砂川　優

4. 肝細胞がん

• 新臨床腫瘍学 改定第7版, 4(35)447-453.
• 梅本久美子

5. 消化器がん治療におけるctDNAの現状と展望

• 医学のあゆみ, 288(2)105-109.
• 武田　弘幸、砂川　優

論文業績（英文）

2024年度

《原著・総説・解説》

1. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).

• Cancer Medicine.
• Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE.

2. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.

• Esophagus.
• Hara H, Satoh T, Kojima T, Tsushima T, Sunakawa Y, Okada M, Ding N, Wu H, Li L, Yu T, Barnes G, Kato K.

3. BAYONET trial: A multicenter phase II trial of staged combination with encorafenib + binimetinib + cetuximab following encorafenib + cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer.

• ESMO Gastrointestinal Oncology.
• Yuki Matsubara, Hideaki Bando, Daisuke Kotani, Yoshinori Kagawa, Kazuaki Harada, Hiroki Osumi, Naoki Izawa, Takeshi Kawakami, Shogen Boku, Toshihiko Matsumoto, Masashi Wakabayashi, Takayuki Yoshino.

2023年度

《原著・総説・解説》

1. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).

• Target Oncol. 18(3):359-368, 2023.
• Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, Yoshio Nagahisa, Kazuhiro Nishikawa, Masazumi Takahashi, Masato Nakamura, Atsushi Ishiguro, Hiroo Katsuya, Jun Hihara, Dai Manaka, Yuji Negoro, Akihito Tsuji, Takao Takahashi, Mitsugu Kochi, Mizutomo Azuma, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa, Masashi Fujii.

2. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.

• Target Oncol. 18(3):369-381, 2023.
• Naoki Izawa, Toshiki Masuishi, Naoki Takahashi, Hirokazu Shoji, Yoshiyuki Yamamoto, Toshihiko Matsumoto, Keiji Sugiyama, Takeshi Kajiwara, Kentaro Kawakami, Naoki Aomatsu, Chihiro Kondoh, Hisato Kawakami, Naoki Takegawa, Taito Esaki, Mototsugu Shimokawa, Kazuto Nishio, Yukiya Narita, Hiroki Hara, Yu Sunakawa, Narikazu Boku, Toshikazu Moriwaki, Takako Eguchi Nakajima, Kei Muro.

3. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).

• ESMO Open. 7(3):100512.
• Sunakawa Y, Satake H, Usher J, Jaimes Y, Miyamoto Y, Nakamura M, Kataoka M, Shiozawa M, Takagane A, Terazawa T, Watanabe T, Ishiguro K, Tanaka C, Takeuchi M, Fujii M, Danenberg K, Danenberg PV, Lenz HJ, Sekikawa T, Ichikawa W.

4. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.

• ESMO Open. 8(3):101558.
• Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, Mulansari NA, Govind Babu K, Lee MA, Tan CK, Cornelio G, Chong DQ, Chen LT, Tanasanvimon S, Prasongsook N, Yeh KH, Chua C, Sacdalan MD, Sow Jenson WJ, Kim ST, Chacko RT, Syaiful RA, Zhang SZ, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G.

5. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.

• Target Oncol. 18(3):369-381.
• Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwara T, Kawakami K, Aomatsu N, Kondoh C, Kawakami H, Takegawa N, Esaki T, Shimokawa M, Nishio K, Narita Y, Hara H, Sunakawa Y, Boku N, Moriwaki T, Eguchi Nakajima T, Muro K.

6. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09).

• Target Oncol. 18(3):359-368.
• Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, Manaka D, Negoro Y, Tsuji A, Takahashi T, Kochi M, Azuma M, Kadowaki S, Michimae H, Sunakawa Y, Ichikawa W, Fujii M.

7. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.

• JCO Precis Oncol. 7:e2200653.
• Nakamura Y, Yamashita R, Okamoto W, Komatsu Y, Yuki S, Ueno M, Kato K, Taniguchi H, Kagawa Y, Denda T, Hara H, Esaki T, Moriwaki T, Sunakawa Y, Oki E, Nagashima F, Nishina T, Satoh T, Kawakami H, Yamaguchi K, Ohtsubo K, Kato T, Horita Y, Tsuji A, Yasui H, Goto M, Hamamoto Y, Wakabayashi M, Ikeno T, Shitara K, Bando H, Tsuchihara K, Miki I, Ichiki H, Ohtsu A, Yoshino T.

8. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.

• Eur J Cancer. 184:10-20.
• Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, Suminaka C, Yamaki M, Sakamoto Y, Kawabata R, Ishiguro A, Akamaru Y, Kito Y, Yabusaki H, Matsuyama J, Takahashi M, Makiyama A, Hayashi H, Chamoto K, Honjo T, Nakagawa K, Ichikawa W, Fujii M.

9. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.

• Br J Cancer. 128(10):1897-1905.
• Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T.

10. Clinial utility of geriatric assessment tools in older patients with gastrointestinal cancer.

• Frontiers in oncology. eCollection 2023.
• Ayako Doi, Takuro Mizukami, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Yoshiki Horie, Naoki Izawa, Takashi Ogura, Yu Sunakawa.

11. Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.

• International journal of clinical oncology. Online ahead of print.
• Mitsuhiko Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita, Naoki Izawa, Saburo Kakizoe, Mototsugu Shimokawa, Tomoharu Yoshizumi, Yoshihiro Kakeji, Masaki Mori, Eiji Oki.

12. Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.

• JCO Precision Oncology. 7:e2200688.
• Yu Aoki, Yoshiaki Nakamura, Tadamichi Denda, Takashi Ohta, Taito Esaki, Manabu Shiozawa, Kensei Yamaguchi, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Naohiro Okano, Hiroya Taniguchi, Taro Sato, Eiji Oki, Tomohiro Nishina, Yoshito Komatsu Nobuhisa Matsuhashi, Masahiro Goto, Hisateru Yasui, Koushiro Ohtsubo, Toshikazu Moriwaki, Naoki Takahashi, Yosuke Horita, Shogen Boku, Masashi Wakabayashi, Takashi Ikeno, Ryuta Mitani, Mihoko Yuasa, Takayuki Yoshino.

13. Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.

• Japanese journal of clinical oncology. 15;hyad062.
• Hiroshi Imaoka, Masafumi Ikeda, Kumiko Umemoto, Yu Sunakawa, Makoto Ueno, Hideki Ueno, Masato Ozaka, Takamichi Kuwahara, Naohiro Okano, Masashi Kanai, Terumasa Hisano, Yuko Suzuki, Akinori Asagi, Kazuhiko Shioji, Akiko Todaka, Kunihiro Tsuji, Kenji Ikezawa, Ikuya Miki, Yoshito Komatsu, Noriyuki Akutsu, Tatsuya Yamashita, Hiroyuki Okuyama, Junji Furuse, Hiroaki Nagano.

14. Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

• British Journal of Cancer, Oct;129(6):1032-1039.
• Eiji Oki, Koji Ando, Yoshiaki Nakamura, Hiroyuki Kitao, Mototsugu Shimokawa, Daisuke Kotani, Hideaki Bando, Tomohiro Nishina, Takanobu Yamada, Satoshi Yuki, Yukiya Narita, Hiroki Hara, Takashi Ohta, Taito Esaki, Yasuo Hamamoto, Ken Kato, Yoshiyuki Yamamoto, Keiko Minashi, Koushiro Ohtsubo, Naoki Izawa, Hisato Kawakami, Takeshi Kato, Taroh Satoh, Naohiro Okano, Akihito Tsuji, Kentaro Yamazaki, Takayuki Yoshino, and Yoshihiko Maehara.

15. Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study

• Target Oncol., Sep;18(5):707-715.
• Seiichiro Mitani, Yosuke Kito, Kaori Hino, Kentaro Kawakami, Naoki Izawa, Fumiyasu Hanamura, Yoshiyuki Yamamoto, Hirokazu Shoji, Azusa Komori, Shogen Boku, Kenji Tsuchihashi, Kyoko Kato, Yoshikane Nonagase, Toshihiko Matsumoto, Mitsuhiro Furuta, Hisato Kawakami.

16. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study

• ESMO OPEN., 27;8(6):102071.
• Y. Narita, T. Matsushima, Y. Sakamoto, H. Matsuoka, H. Tanioka, T. Kawakami, H. Shoji, T. Mizukami, N. Izawa, T. Nishina, Y. Yamamoto, S. Mitani, M. Nakamura, T. Misumi, K. Muro.

17. Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)

• British Journal of Cancer.
• Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Hitoshi Arioka, Hirotoshi Iihara, Mitsuhiro Sugawara, Hajime Morita, Ayako Mochizuki, Shuichi Nawata, Keisuke Mishima, Ayako Tsuboya, Tempei Miyaji, Kazunori Honda, Ayako Yokomizo, Naoya Hashimoto, Takeshi Yanagihara, Junki Endo, Takashi Kawaguchi, Naoki Furuya , Yumiko Sone, Yusuke Inada, Yasushi Ohno, Chikatoshi Katada, Naoya Hida, Kana Akiyama, Daisuke Ichikura, Akiko Konomatsu, Takashi Ogura, Takuhiro Yamaguchi, Takako Eguchi Nakajima.

18. Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials

• Cancer Medicine.
• Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii.

19. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

• Journal of clinical oncology., Dec 20;41(36):5569-5578
• Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do-Youn Oh, Alicia Okines, David M O’Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas E Stinchcombe, Tanios Bekaii-Saab.

20. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

• ESMO　OPEN., Oct;8(5):101636
• H Yasui, Y Okita, M Nakamura, T Sagawa, T Watanabe, K Kataoka, D Manaka, K Shiraishi, N Akazawa, T Okuno, T Shimura, M Shiozawa, Y Sunakawa, H Ota, M Kotaka, H Okuyama, M Takeuchi, W Ichikawa, M Fujii, A Tsuji.

21. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study

• Cancer Medicine., Sep;12(18):18702-18716
• Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake , Atsuo Takashima, Nobuhisa Matsuhashi, Takeshi Kato, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino.

22. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

• Gastric Cancer., 26(6):1063-1068
• Yasuhiro Kodera, Kazuhiro Yoshida, Mitsugu Kochi, Takeshi Sano, Wataru Ichikawa, Yoshihiro Kakeji, Yu Sunakawa, Masahiro Takeuchi, Masashi Fujii.

23. The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer

• Future oncology., 19(17):1165-1174
• Chiaki Inagaki, Ryo Matoba, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Eisuke Inoue, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa.

24. Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment

• Japanese journal of clinical oncology., 53(9):764-773
• Hiroshi Imaoka, Masafumi Ikeda, Kumiko Umemoto, Yu Sunakawa, Makoto Ueno, Hideki Ueno, Masato Ozaka, Takamichi Kuwahara, Naohiro Okano, Masashi Kanai, Terumasa Hisano, Yuko Suzuki, Akinori Asagi, Kazuhiko Shioji, Akiko Todaka, Kunihiro Tsuji, Kenji Ikezawa, Ikuya Miki, Yoshito Komatsu, Noriyuki Akutsu, Tatsuya Yamashita, Hiroyuki Okuyama, Junji Furuse, Hiroaki Nagano.

25. Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas

• Journal of Gastrointest Oncology., 14(5):2083-2096
• Bennett A Caughey, Kumiko Umemoto, Michelle F Green, Masafumi Ikeda, Melissa E Lowe, Makoto Ueno, Donna Niedzwiecki, Hiroya Taniguchi, Daniel J Walden, Yoshito Komatsu, Rachel D’Anna, Taito Esaki, Tadamichi Denda, Michael B Datto, Hideaki Bando, Tanios Bekaii-Saab, Takayuki Yoshino, John H Strickler, Yoshiaki Nakamura.

26. The Phase I/II eNRGy Trial: Zenocutuzumab in Patients with Cancers Harboring NRG1 Gene Fusions

• Future Oncology.
• Dong-Wan Kim, Alison M. Schram, Antoine Hollebecque, Kazumi Nishino, Teresa Macarulla, Sun Young Rha, Michaël Duruisseaux, Stephen V. Liu, Mohammed Najeeb Al Hallak, Kumiko Umemoto, Claas Wesseler, James M. Cleary, Christoph Springfeld, Cindy Neuzillet, Andrew Joe, Shekeab Jauhari, Jim Ford, Koichi Goto.

27. Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials

• Cancer Medicine.,13(1):e6818
• Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii.

28. CCCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value

• J Immunother Cancer.,12(1):e007939
• Francesca Battaglin, Yasmine Baca, Joshua Millstein, Yan Yang, Joanne Xiu, Hiroyuki Arai, Jingyuan Wang, Fang-Shu Ou, Federico Innocenti, Shannon M Mumenthaler, Priya Jayachandran, Natsuko Kawanishi, Annika Lenz, Shivani Soni, Sandra Algaze, Wu Zhang, Taline Khoukaz, Evanthia Roussos Torres, Andreas Seeber, Jim P Abraham, Emil Lou, Philip A Philip, Benjamin A Weinberg, Anthony F Shields, Richard M Goldberg, John L Marshall, Alan P Venook, W Michael Korn, Heinz-Josef Lenz.

29. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer

• Ther Adv Med Oncol.,16:17588359231217967
• Kubota Y, Shitara K.

30. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

• Eur J Cancer.,201:113914
• Hiroyuki Arai, Yan Yang, Yasmine Baca, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Yohei Kubota, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Sandra Algaze, Shivani Soni, Wu Zhang, Richard M Goldberg, Michael J Hall, Aaron James Scott, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, John Marshall, Sanjay Goel, Joanne Xiu, W Michael Korn, Alan P Venook, Yu Sunakawa, Heinz-Josef Lenz.

31. Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: Results of the Japanese expanded access program

• Clinical Colorectal Cancer.,S1533-0028(24)00022-7
• Daisuke Kotani, Atsuo Takashima, Takeshi Kato, Taroh Satoh, Toshiki Masuishi, Yoshito Komatsu, Manabu Shiozawa, Taito Esaki, Naoki Izawa, Shinji Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, Toshifumi Yamaguchi, Hiroya Taniguchi, Yasunori Ushida, Toshiya Oizaki, Chiaki Inoue, Takayuki Yoshino.

32. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G

• Targeted Oncology.,19(2):181-190
• Toshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, Toshiki Masuishi, Yasushi Tsuji, Hirokazu Shoji, Kenro Hirata, Takao Tsuduki, Akitaka Makiyama, Naoki Izawa, Naoki Takahashi, Masahiro Tsuda, Hisateru Yasui, Takashi Ohta, Yosuke Kito, Satoshi Otsu, Shuichi Hironaka, Kentaro Yamazaki, Narikazu Boku, Ichinosuke Hyodo, Kenichi Yoshimura & Kei Muro.

33. Microsatellite instability: A 2024 update

• Cancer Science.
• Hiroyuki Yamamoto, Yoshiyuki Watanabe, Hiroyuki Arai, Kumiko Umemoto, Keisuke Tateishi, Yu Sunakawa.

34. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.

• Journal of clinical oncology.
• Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O’Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T.

35. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.

• Targeted Oncology.
• Sunakawa Y, Kuboki Y, Watanabe J, Terazawa T, Kawakami H, Yokota M, Nakamura M, Kotaka M, Sugimoto N, Ojima H, Oki E, Kajiwara T, Yamamoto Y, Tsuji Y, Denda T, Tamura T, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T.

36. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.

• Clinical Colorectal Cancer.
• Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kanazawa A, Ando K, Horita Y, Goto M, Okano N, Moriwaki T, Satoh T, Tsuji A, Yamashita K, Asano C, Abe Y, Nomura S, Yoshino T.

2022年度

《原著・総説・解説》

1. Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment.

• Nutr Cancer, 74(2):539-545, 2022.
• Mizukami T, Hamaji K, Onuki R, Yokomizo A, Nagashima Y, Takeda H, Umemoto K, Doi A, Arai H, Hirakawa M, Horie Y, Izawa N, Ogura T, Tsuda T, Sunakawa Y, Shibata M, Tanaka T, Mikami S, Nakajima TE.

2. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.

• ESMO Open, 7(2):100415, 2022.
• Izawa N, Shiokawa H, Onuki R, Hamaji K, Morikawa K, Saji H, Ohashi H, Kasugai S, Hayakawa N, Ohara T, Sunakawa Y

3. Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.

• JCO Precis Oncol, Apr;6:e2100535., 2022.
• Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, Kagawa Y, Denda T, Satoh T, Yamazaki K, Sunakawa Y, Kato T, Goto M, Yuki S, Nishina T, Oki E, Shinozaki E, Matsuhashi N, Takahashi N, Tsuji A, Ohtsubo K, Wakabayashi M, Ikeno T, Hata M, Odegaard JI, Yoshino T.

4. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.

• Anticancer Res, 42(5)：2675-2681, 2022.
• Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, Denda T, Takagane A, Watanabe T, Kotaka M, Nakamura M, Sunakawa Y, Takeuchi M, Ichikawa W, Fujii M.

5. Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.

• Clin Colorectal Cancer, 21(3)：259-266, 2022.
• Hiroyuki Arai, Joshua Millstein, Yan Yang, Sebastian Stintzing, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, V3olker Heinemann, Heinz-Josef Lenz.

6. NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).

• J Cancer Res Clin Oncol, 148(10):2841-2854, 2022.
• Kajiwara T, Nishina T, Nakasya A, Yamashita N, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Moriwaki T, Denda T, Ohtsubo K, Sunakawa Y, Horita Y, Kawakami H, Kato T, Satoh T, Ando K, Mizutani T, Yasui H, Goto M, Okuyama H, Yamazaki K, Yoshino T, Hyodo I.

7. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling.

• J Natl Cancer Inst, 114(9):1279-1286, 2022.
• Umemoto K, Yamamoto H, Oikawa R, Takeda H, Doi A, Horie Y, Arai H, Ogura T, Mizukami T, Izawa N, Moore JA, Sokol ES, Sunakawa Y.

8. Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.

• Targeted Oncology, 17(3):343-353, 2022.
• Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, Kato K, Hara H, Denda T, Yamamoto Y, Shiozawa M, Oki E, Okamoto W, Yoshino T, Eguchi Nakajima T.

9. fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing.

• Bioinform Adv, 13;2(1):vbac047, 2022.
• Joshua Millstein, Francesca Battaglin, Hiroyuki Arai, Wu Zhang, Priya Jayachandran, Shivani Soni, Aparna R Parikh, Christoph Mancao, Heinz-Josef Lenz.

10. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.

• Eur J Cancer, 21;172:22-30, 2022.
• Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Yan Yang, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Tianshu Liu, Volker Heinemann, Alfredo Falcone, Lin Shen, Joshua Millstein, Heinz-Josef Lenz.

11. Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol.

• Contemporary Clinical Trials Communications, 29:doi-10.1016/j.conctc.2022.100967, 2022.
• Higashibata Takahiro, Hamano Jun, Kessoku Takaomi, Kajiura Shinya, Hirakawa Mami, Horie Yoshiki, Shimizu Masaki, Oyamada Shunsuke, Ariyoshi Keisuke, Kihara Kota, Yamanaka Yohei, Konishi Kumi, Doki Kosuke, Takashima Yasuyuki, Horiuchi Manabu, Homma Masato, Yamada Takeshi, Yamamoto Yoshiyuki, Moriwaki Toshikazu, Morita Tatsuya, Nakajima Atsushi, Nagaoka Hiroka

12. A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

• ESMO Open, 2022 Dec;7(6):100592, 2022.
• Okamoto W, Sakai K, Makiyama A, Yamamoto Y, Shitara K, Denda T, Izawa N, Nakano Y, Nishina T, Esaki T, Hara H, MiuraY, Boku N, Yamazaki K, Hironaka S, Misumi T, Hyodo I, Muro K, Nishio K.

13. Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience

• Cancer Management and Research, (14):3083-3094, 2022.
• Yohei Kubota, Yu Aoki, Akihito Kawazoe, Kohei Shitara.

14. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

• Invest New Drugs, 40(5):1021-1031, 2022.
• Shimizu T, Nakajima TE, Yamamoto N, Yonemori K, Koyama T, Kondo S, Sunakawa Y, Izawa N, Horie Y, Xiang S, Xu S, Qin L, Gong J, Liu D.

15. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer

• The Oncologist,27(10):e774-e782, 2022.
• Kobayashi, S.Suzuki, M.Ueno, M.Maruki, Y.Okano, N.Todaka, A.Ozaka, M.Tsuji, K.Shioji, K.Doi, K.Kojima, Y.Tsumura, H.Tanaka, K.Higuchi, H.Kawabe, K.Imaoka, H.Yamashita, T.Miwa, H.Nagano, H.Arima, S.Hayashi, H.Naganuma, A.Yamaguchi, H.Hisano, T.Umemoto, K.Ishii, S.Nakashima, K.Suzuki, R.Kitano, Y.Misumi, T.Furuse, J.Ishii, H.

16. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

• Invest New Drugs,40(5):1021-1031, 2022.
• Shimizu T, Nakajima TE, Yamamoto N, Yonemori K, Koyama T, Kondo S, Sunakawa Y, Izawa N, Horie Y, Xiang S, Xu S, Qin L, Gong J, Liu D.

17. Nivolumab for treating patients with occupational cholangiocarcinoma

• J Hepatobiliary Pancreat Sci.,29(11):1153-1155, 2022.
• Shogo Tanaka, Kumiko Umemoto, Shoji Kubo, Yasunori Sato, Sachiyo Mimaki, Katsuya Tsuchihara, Shigekazu Takemura, Hiroji Shinkawa, Akira Mori, Masafumi Ikeda.

18. Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study

• BMC cancer.,22(1):1322-1322, 2022.
• Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Izawa N, Nakashima K, Horie Y, Yagisawa M, Kajiura S, Ando T, Mitsuhashi Y, Sunakawa Y, Kikuchi Y, Komatsu Y.

19. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis

• Pancreatology, 22(8):1159-1166, 2022.
• Yoshida, Y.Kobayashi, S.Ueno, M.Morizane, C.Tsuji, K.Maruki, Y.Mori, K.Watanabe, K.Ohba, A.Furuta, M.Todaka, A.Tsujimoto, A.Ozaka, M.Okano, N.Yane, K.Umemoto, K.Kawamoto, Y.Terashima, T.Tsumura, H.Doi, K.Shioji, K.Asagi, A.Kojima, Y.Suzuki, E.Toshiyama, R.Furukawa, M.Naganuma, A.Suzuki, R.Miwa, H.Ikeda, M.Furuse, J.

20. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer

• ESMO Open, 8(1):100762, 2022.
• Y.Kubota, A.Kawazoe, S.Mishima, Y.Nakamura, D.Kotani, Y.Kuboki, H.Bando, T.Kojima, T.Doi, T.Yoshino, T.Kuwata, K.Shitara

21. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

• British Journal of Cancer, 128:1603-1608, 2022.
• Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu, S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard J. I, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C.

22. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study

• The Lancet Oncology, 24(2):151-161, 2022.
• Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Liu T, Oberley M, Spetzler D, Korn WM, Shen L, Lenz HJ.

23. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials.

• eClinicalMedicine, 57:101827, 2022.
• Wang J, Millstein J, Yang Y, Stintzing S, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Mancao C, Cremolini C, Liu T, Heinemann V, Falcone A, Shen L, Lenz HJ.

24. Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.

• Invest New Drugs, 40(5):1032-1041.
• Sunakawa Y, Takahashi K, Kawaguchi O, Yamamoto N.

25. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.

• N Engl J Med, 388(1):33-43.
• Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS.

過去の業績

• 2021年度（PDF）
• 2020年度（PDF）
• 2019年度（PDF）
• 2018年度（PDF）
• 2017年度（PDF）
• 2016年度（PDF）
• 2015年度（PDF）
• 2014年度（PDF）

書籍のご紹介

チャートでわかる！
がん外来化学療法のリアル

チームで解決する18の副作用

（編集）聖マリアンナ医科大学病院腫瘍センター

ご購入はこちら